To include your compound in the COVID-19 Resource Center, submit it here.
Oxford stopped an open-label, U.S. Phase II trial comparing TroVax plus docetaxel vs. docetaxel alone in patients with metastatic HRPC
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury